No registrations found.
ID
Source
Brief title
Health condition
immune respons
pneumococcal vaccination
pneumococcal conjugate vaccination
PCV13
pneumonia
Sponsors and support
Intervention
Outcome measures
Primary outcome
Immune response to pneumococcal vaccination in patients who were diagnosed with CAP due to S. pneumoniae in comparison with patients with another causative pathogen. Main parameters are antibody titres against the different
pneumococcal serotypes before and after vaccination and avidity maturation of these antibodies.
Secondary outcome
• To investigate antibody response after pneumococcal vaccination in patients with community acquired pneumococcal
pneumonia in the past who failed to elicit a specific antibody response previously.
• To investigate the cellular immune responses after pneumococcal vaccination in patients with community acquired pneumococcal pneumonia in the past compared to pneumonia patients with another pathogen.
• To investigate quality of life by the RAND-36 score in patients with a community acquired pneumonia in the past.
• To investigate the long-term mortality after community acquired pneumococcal pneumonia.
Background summary
NA
Study objective
The immune response to pneumococcal vaccination in patients after community acquired
pneumonia with S. pneumoniae is different compared to pneumonia patients with another pathogen.
Study design
1) Week 1, first blood draw, vaccination, RAND36.
2) After 3-4 weeks, second blood draw.
Intervention
13-valent pneumococcal conjugate vaccination, prevenar 13 (PCV13)
G. Wagenvoort
Nieuwegein 3435 CM
The Netherlands
0883203000
g.wagenvoort@antoniusziekenhuis.nl
G. Wagenvoort
Nieuwegein 3435 CM
The Netherlands
0883203000
g.wagenvoort@antoniusziekenhuis.nl
Inclusion criteria
1. Patients who participated in the Ovidius or Triple-P study (2004-2009).
2. Diagnosis in these studies with pneumococcal pneumonia or pneumonia due another identified organism.
3. Age > 18 years.
4. Signing of informed consent.
Exclusion criteria
Changed 2-sep-2014:
1. Diagnosis of pneumonia without an identified causative organism.
2. Fever at time of vaccination.
3. Previous/known allergic reaction to any of the components of the vaccine given.
4. Mentally incompetent.
5. Previous pneumococcal conjugate vaccination.
6. Pneumococcal polysaccharide vaccination within 6 months prior to inclusion.
7. Clinical pneumonia within 1 month prior to inclusion.
Design
Recruitment
IPD sharing statement
Followed up by the following (possibly more current) registration
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| NTR-new | NL4221 |
| NTR-old | NTR4460 |
| CCMO | NL44924.100.13 |
| OMON | NL-OMON40285 |